StockNews.com assumed coverage on shares of IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the construction company’s stock.
IGC Pharma Stock Performance
Shares of IGC opened at $0.51 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.85 and a quick ratio of 0.86. IGC Pharma has a twelve month low of $0.25 and a twelve month high of $0.91. The company has a market capitalization of $33.94 million, a price-to-earnings ratio of -1.95 and a beta of 1.71.
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The construction company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million for the quarter. IGC Pharma had a negative net margin of 1,163.24% and a negative return on equity of 110.37%.
Institutional Inflows and Outflows
About IGC Pharma
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.
Further Reading
- Five stocks we like better than IGC Pharma
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- AMD is Down 35%. Now is the Time to Buy the Dip
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Amazon Stands Tall: New Highs Are in Sight
- What is a Dividend King?
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.